device in patients with CS. Of importance is that the potential risk of right heart failure with LVAD use is also a challenge, especially in high-risk candidates for LVAD. 19- 21 In contrast, not only can extracorporeal membrane oxygenation (ECMO) provide immediate and adequate systemic circulation and oxygenation, but its procedure is also much more simple and requires a shorter time to complete as compared with LVAD. 6,7, 15 Indeed, our recent data has shown that ECMO provides lifesupport and improved clinical outcome for patients with STsegment elevation myocardial infarction (STEMI) complicated by profound CS who are undergoing primary percutaneous coronary intervention (PCI). 15 In actual clinical practice, however, the etiologies of CS are multiple and complicated STEMI merely comprises a part of the whole spectrum. 6, 7 Whether ECMO support is still effective for patients with CS from causes other than STEMI has not been fully investigated. Accordingly, this single-center observational study was designed to analyze the outcome of patients with profound CS related to STEM who are undergoing primary PCI and prompt ECMO support in a catheterization room, and those patients with unrelated STEMI who are undergoing cardiopulmonary cerebral resuscitation (CPCR) and prompt ECMO support.
Methods

Patient Population
Our hospital has started the program of portable ECMO for patients with profound CS since May 2003. The ECMO team consisted of 3 senior cardiovascular surgeons, 2 senior interventional cardiologists, several senior bypass technicians, and a senior nurse. The agility of the team allowed ECMO to be performed in a catheterization room, at the bedside, in an operation room, in an emergency room, and in a cardiac intensive care unit (ICU).
Inclusion Criteria for ECMO Support
Indication for ECMO support included all patients who experienced profound CS refractory to conventional therapy, including a maximal dose of vasopressor agent (intravenous administration of dopamine >20 μg · kg -1 · min -1 ) and/or IABP support and CPCR >10-15 min without brain death (ie, immediate CPCR after onset of CS to meet the minimal circulatory requirement). All enrolled patients received ECMO-CPR (to gain recovery of spontaneous circulation by ECMO) (a majority of these patients [ie, >95%] were unrelated to STEMI) or persisting profound shock after recovery of spontaneous circulation from cardiac arrest without ECMO-CPR (a majority of these patients [ie, >85%] were STEMI).
For the purpose of the study, all patients with profound CS undergoing CPCR and prompt ECMO rescue were prospectively identified and enrolled. The detailed procedure and protocol has been described in our recent report. 15 
Categorization of Patients Into Subgroups of CS Based on the Etiologies
Between October 2003 and October 2010, a total of 154 patients with profound CS undergoing CPCR followed by prompt ECMO support were prospectively identified. Twenty patients who experienced acute respiratory distress syndrome undergoing ECMO support were also excluded. Thus, the remaining 134 patients (87.0%) with profound CS were prospectively recruited for this study. These patients were further catego- Figure 1 . Schematic overview of the study enrollment. ARD, adult respiratory distress syndrome; CDH, congenital diaphragmatic hernia; CHF, congestive heart failure; STEMI, ST-segment elevation myocardial infarction. Impact of ECMO on Cardiogenic Shock rized into the following subgroups: (1) STEMI (n=37); (2) non-STEMI (n=16); (3) post-surgery pump failure (n=30); (4) refractory congestive heart failure (CHF) unresponsive to medication (n=14); (5) fulminant acute myocarditis (n=26); (6) pediatric congenital diaphragmatic hernia (n=3); and (7) cardiac catheterization-related severe complications (n=8) (Figure 1) .
The complications of cardiac catheterization included: left main coronary artery dissection (n=1), right coronary dissection complicated by severe retrograde aortic dissection (n=2), coronary artery perforation complicated with cardiac tamponade (n=2), right ventricular biopsies complicated by perforation and cardiac tamponade (n=2), and acute high-burden thrombus formation in the left coronary artery during PCI complicated by no reflow phenomenon and refractory ventricular tachycardia (VT)/ventricular fibrillation (VF) refractory to defibrillation and anti-arrhythmia medication (n=1). Between October 2003 and October 2010, a total of 9,100 patients who experienced obstructive coronary artery disease underwent PCI at our institute. Thus, the incidence of PCI complicated with profound CS undergoing ECMO rescue was 0.07% (6/9,100).
This was an observational study. The study protocol has been approved by the Institutional Review Committee on Human Research of Kaohsiung Chang Gung Memorial Hospital (institutional review board [IRB] number: 100-0407B) and all the participates had given their informed consents both for the study and publication of their data.
Procedure and Protocol
For patients undergoing PCI, a transradial artery approach using a 6-French arterial sheath is routinely performed at our institute unless an Allen's test is positive on both sides. A 6-French Kimny guiding catheter (Boston Scientific, Scimed, Inc, Maple Grove, MN, USA) was used for both the diagnosis of obstructive coronary artery disease and therapeutic intervention. IABP support was performed via the right femoral artery in patients experiencing acute pulmonary edema associated with an unstable pulmonary condition or hemodynamic instability.
Definitions
Definitions of CS and profound CS were based on our previous reports. 13, 15 Briefly, patients who developed CS met the following prospectively defined criterion: Chest X-ray showing pulmonary edema with systolic blood pressure (SBP) <80 mmHg and requiring vasopressing agent infusion. In addition, profound shock was defined as a SBP <75 mmHg despite intravenous inotropic agent administration and IABP support, which was associated with altered mental status and respiratory failure while undergoing CPCR.
Procedure and Management of ECMO
For adult patients, the management procedure has been reported in detail in our recent study. 15 Briefly, the ECMO system consisted mainly of a heparin-bound centrifugal pump and a hollow-fiber microporous membrane oxygenator (Terumo, Asitaka, Japan). The entire system and all instruments for vascular access were put on a mobile cart to facilitate prompt transportation within the institute, including the catheterization room, emergency room, ICU, and operation room. The ECMO system was quickly set up through the femoral venoarterial route by percutaneous puncture.
The tip of the arterial cannula (18 French) was estimated to reside at the aorto-iliac junction, whereas the tip of the venous cannula (18 French) was set at the junction between the inferior vena cava and the right atrium. The locations of the catheters were confirmed radiographically in the catheterization room or by estimating the distance between the puncture site and the level of the right atrium elsewhere at the institute. A catheter was placed for antegrade reperfusion if distal limb perfusion was inadequate.
Heparinization continued to maintain an activated clotting time between 150 and 180 s in the absence of a hemorrhage. For severe hemorrhagic complications, heparinization was temporarily held for 12 h before adjustment of dosage.
The pump flow was initially set at approximately 2-3 L/min with dopamine to maintain a mean blood pressure ≥55 mmHg. The flow was then increased to a full flow of 3.5-4.0 L/min to maintain a mean blood pressure >70 mmHg.
The circuit, including the pump head and oxygenator, was replaced under certain conditions, for example: (1) a marked plasma leak; (2) hemoglobinuria; (3) and/or blood clot formation in the circuit system. Serial cardiac enzymes were routinely checked and transthoracic echocardiography was performed daily by a cardiologist to assess the recovery of heart function.
For pediatric patients, carotid artery and internal jugular vein approaches were preferred. According to the size of carotid artery, an 8-12 French arterial and venous cannula was chosen for the patients. The pump flow was initially started up and then maintained at 100 ml · kg -1 · min -1 to provide a mean blood pressure ≥55 mmHg.
ECMO Weaning Protocol
For all patients, receiving ECMO support for at least 48 h before weaning was attempted. If the patient's hemodynamic and general condition became stable with echocardiographic evidence of improvement in left ventricular contractility (>40% of left ventricular ejection fraction), an inotropic agent was then carefully tapered. Moreover, the oxygen saturation was continuously monitored until the mixed venous oxygen saturation was ≥70% without any deterioration in hemodynamic status, and the pump flow was reduced gradually to 500 ml/min for adult patients and 20-25 ml · kg -1 · min -1 for pediatric patients. Finally, ECMO was withdrawn when sustained stability was noted in a patient's hemodynamic status.
Successful weaning was defined as survival for 72 h after the successful removal of ECMO. Survival was defined as weaning from ECMO, followed by continued survival until hospital discharge.
Data Collection and the End Points
For the purpose of the current study, all patients undergoing ECMO support were prospectively identified. Detailed in-hospital and follow-up data including age, gender, coronary risk factors, Killip score on admission, peak level of creatine kinase (CK), New York Heart Association Functional Classification, number of diseased vessels, in-hospital adverse events, and 30-day mortality were obtained. These data were collected prospectively and entered into a digital database. The primary end point of this study was defined as a successful weaning from ECMO and a 30-day survival rate. The secondary end point was to establish the factors for alive discharge.
Statistical Analysis
Data were expressed as mean ± SD or % (number). Univariate and multiple stepwise logistic regression analyses were used for determining the predictors of in-hospital mortality. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC, USA). A P value of <0.05 was considered statistically significant. CHUNG SY et al. Table 1 shows the baseline characteristics of 134 study patients with a mean age of 51.8 years. The population was malepredominant (>77%). Current smoking was the most predominant coronary artery disease risk factor. The incidence of either old stroke or prior myocardial infarction was less than 11%.
Results
Relevant Baseline Characteristics of Study Patients
The mean systolic and diastolic blood pressures were extremely low at 49.8 mmHg and 29.6 mmHg, respectively, prior to ECMO implementation. Additionally, the majority of study patients received simultaneous IABP and ECMO support. Furthermore, more than 91.8% of the patients experienced acute respiratory failure that required mechanical ventilatory support prior to ECMO. Moreover, a chest X-ray showed that more than 87.3% of the patients experienced acute pulmonary edema prior to ECMO support. Besides, the mean Acute Physiology and Chronic Health Evaluation (APACHE) II score was remarkably high in the study patients. These findings implied that the study patients had a very advanced illness and were in an extremely unstable condition.
Laboratory findings showed that the peak serum level of CK was substantially elevated. Additionally, an abnormally elevated serum level of creatinine, an index of renal function impairment, was observed prior to ECMO. A more prominent increase was noted 48 h after starting ECMO. Table 2 shows the categorization and relevant clinical characteristics of the 134 study patients. In the current study, the incidences of profound CS related to STEMI, which was observed during catheterization for patients undergoing primary PCI, and non-STEMI prior to PCI were 27.6% and 11.9%, respectively. Additionally, the incidence of profound CS resulted from post-surgery pump failure, including rupture of the abdominal aorta or aortic dissection (n=9), chest trauma (n=1), heart transplantation surgery (n=1), liver transplantation surgery (n=1), ischemic bowel surgery (n=1), valvular heart disease surgery (n=8), coronary artery bypass graft (CABG) surgery (n=5), combined valvular heart disease and CABG surgery (n=4), was 22.4% (n=30). Furthermore, the occurrence of profound CS resulted from refractory CHF unresponsive to medication, including VT/VF (n=1), dilated cardiomyopathy-related advanced CHF (n=5) and valvular heart disease (n=5), massive pulmonary embolism (n=2) (1 due to a fat embolism and another 1 due to a post-partum hemorrhage/embolism) and acute rejection after heart transplantation (n=1), and was 10.5% Troponin-I (mean ± SD) 33.9±112.9
Categorization, Clinical Characteristics, and Outcome of ECMO-Supported Patients
Peak level of CK (IU/L) (mean ± SD) 5,311±13,100
Creatinine level before ECMO support (mg/dl) (mean ± SD)
1.9±1.9
Creatinine level after ECMO support (mg/dl) (mean ± SD)*
2.9±2.2
White blood cell count (×10 3 /ml) (mean ± SD) 15.9±10.9
ECMO, extracorporeal membrane oxygenation; MVS, mechanical ventilatory support; APACHE, Acute Physiology and Chronic Health Evaluation; CK, creatine kinase. *Indicats the serum level of creatinine was measured 48 h after ECMO implantation. Refractory CHF failed to medication*, % (n) 10.5 (14) Fulminant acute myocarditis, % (n) 19.4 (26) Pediatric congenital diaphragmatic hernia, % (n)
(3)
Cardiac catheterization-related severe complications, % (n) In-hospital mortality, % (n) 57.5 (77)
Death while waiting for a heart transplantation, % (n) 7.8 (6/77) *Defined as advanced CHF with compromised hemodynamics. † This complication required antegrade blood-flow reperfusion to save the ischemic leg. ECMO, extracorporeal membrane oxygenation; CS, cardiogenic shock; CHF, congestive heart failure; CABG, coronary artery bypass grafting. Impact of ECMO on Cardiogenic Shock (n=14). Moreover, the incidences of profound CS resulted from fulminant acute myocarditis, pediatric congenital diaphragmatic hernia, and cardiac catheterization-related severe complication and were 19.4%, 2.2%, and 6.0%, respectively. ECMO was successfully set up for each patient. The vascular complication related to ECMO was found in 4 patients due to below popliteal artery ischemia, which required antegrade reperfusion. The incidence of antibiotic use with respect to suspicious sepsis was 89.6%. Additionally, the incidence of acute stroke, including intra-cranial hemorrhage (n=7) and ischemic stroke (n=10) was found to be 12.7% (n=17) during hospitalization. Twelve of these 17 patients expired during hospitalization. Of the six patients receiving coronary bypass surgery undergoing ECMO support, 2 succumbed during hospitalization.
The mean duration of ECMO support was 5.1 days. Sixtyeight (50.7%) patients underwent successful weaning from ECMO. Of these 68 patients, 57 (42.5%) were uneventfully discharged, giving a survival rate of 83.8% (57/68) for those with successful weaning. Conversely, 66 (49.3%) patients failed to wean from ECMO and all of them succumbed during hospitalization.
The mean duration of hospitalization in the study patients was 27 days. The 30-day mortality rate was 45.5%. In addition, the in-hospital mortality rate was 57.5% (77). Of these 77 mortalities, heart transplantation had been scheduled for 6 patients but there were no suitable donors. Table 3 shows the in-hospital outcome of different subgroups of patients. The poorest prognostic outcome was among those undergoing cardiac catheterization with a complication of profound CS. Even though the salvage procedures were immediately performed and ECMO support was promptly set up, all of these patients still subsequently succumbed to the severe complications. The other subgroups of patients with adverse prognostic outcome also included those experiencing postsurgery pump failure, refractory CHF unresponsive to medication, and non-STEMI. In contrast, patients with pediatric congenital diaphragmatic hernia, STEMI and fulminant acute myocarditis had the best prognostic outcomes.
Rates of Survival and Mortality in Each Group
Univariate and Multivariate Analysis of Predictors of In-Hospital Outcome
Univariate analysis demonstrated that the APACHE II score was the strongest predictor of in-hospital mortality. In contrast, successful weaning from ECMO was most strongly predictive Cardiac catheterization-related severe complications, % (n)* 8 0 (0) 100 (8) STEMI, ST-segment elevation myocardial infarction; CHF, congestive heart failure. *In these patients, both coronary artery dissection and perforation were completely sealed-off by stent implantation, and the cardiac tamponade was resolved by pericardiocentesis and drainage. Table 1 . *Indicates the data to be presented as continuity. † Discriminate analysis was used to find out a cut-off value for the APACHE II score, which was the most significant value with good sensitivity and specificity for predicting in-hospital mortality. Tables 1,4 .
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of free in-hospital survival. Additionally, male gender, current smoking and respiratory failure were significantly associated with in-hospital mortality. Of importance is the fact that multivariate analysis showed an APACHE II score ≥22 and that this was the only independent predictor of in-hospital mortality, whereas successful ECMO weaning was the only independent determinant of free in-hospital survival ( Tables 4,5 ). Figure 2 shows the cumulative survival rate in the study patients after implementation of ECMO (ie, duration from ECMO support to patient's death or hospital discharge). Kaplan-Meier analysis showed a 30-day free survival rate of 54.5% in the study patients.
Cumulative Survival Rate
Discussion
In spite of the advanced state-of-the-art cardiac life support (ACLS) strategy, the mortality rate of adult in-hospital cardiac arrest of a cardiac origin remains extremely high (ie, more than 85%) if effective circulation cannot be resumed after continuous CPCR for more than 30 min. 7,22, 23 The ACLS guideline, therefore, recommends 30 min as the cutoff point after which CPCR should be considered futile. 24 In the current study, all of our patients experienced profound CS prior to ECMO support. The ECMO team was summoned after CPCR had taken place for more than 10-15 min. Moreover, because the duration between calling the ECMO team and the successful setting up of ECMO lasted for at least 10-15 min, the total time from starting CPCR to complete set-up of ECMO was approximately 25-30 min. The most important finding in the present study is that the survival rate of patients with profound CS from heterogeneous causes of cardiovascular origin was 54.5% by day 30 (Table 2, Figure 2 ) and the in-hospital survival rate was 42.5% (Table 2) . Accordingly, as compared with the conventional CPCR technique, 7,22-24 our findings suggest that ECMO support could offer an additional life-saving benefit in the setting of profound CS. Interestingly, 1 recent clinical observational study has shown that ECMO-supported CPCR provided a short-term and longterm survival benefit over conventional CPR in patients with in-hospital cardiac arrest of a cardiac origin. 7 Further analysis of the results in that study showed that the 30-day survival rate of ECMO-supported CPCR and conventional CPCR was 33.9% and 15%, respectively. 7 Our results, therefore, in addition to corroborating the findings of that study, 7 also encourage the use of ECMO-supported CPCR for those patients with a potential chance of survival.
Another principal finding of the current study is the fact that not all of the patient subgroups had a similar in-hospital prognostic outcome despite the implementation of ECMO-supported CPCR. Our findings showed that the poorest prognostic outcome was among those with profound CS that resulted from non-primary PCI or complications from right ventricular biopsy even though the complication was subsequently resolved by experienced interventional cardiologists. In contrast, the best prognostic outcome was among those experiencing profound CS related to STEMI who were undergoing primary PCI, fulminant acute myocarditis and pediatric congenital diaphragmatic hernia.
Another finding of importance is that successful weaning from ECMO support was independently predictive of free survival and uneventful hospital discharge. Conversely, failure in weaning from ECMO was strongly associated with in-hospital mortality. Consistently, 1 recent study has also shown that successful ECMO weaning was strongly associated with inhospital survival in patients with acute myocardial infarction complicated with refractory shock. 6 Interestingly, despite the fact that all patients who were not successfully weaned from ECMO died in hospital, the duration from onset of ECMO support to expiration was prolonged with a mean of 20±74.9 days. This finding, in addition to supporting the importance of restoring systemic circulation and providing a period for cardiac functional recovery through ECMO, might also provide the critical time for working out an effective management strategy for patients in the future with similar conditions to those reported in our present study.
Currently, the APACHE II score remains one of the most useful ICU assessment tools for the prognostic outcome of critical patients. 25, 26 In the present study, we found that the APACHE II score was a strongly independent predictor of unfavorable in-hospital outcome. Therefore, our findings strengthen those of the previous reports. 25, 26 An essential finding in the current study was that the survival rate was extremely different as a result of subgroup analyses of these heterogeneous causes of CS. Several reasons could explain the favorable outcome of patients with STEMI undergoing primary PCI, fulminant acute myocarditis and pediatric congenital diaphragmatic hernia and a poor prognostic outcome of cardiac catheterization complications. First, as 15 suggested, early ECMO-assisted primary PCI improved the short-term clinical outcome in the setting of STEMI with complicated profound CS. In the current study, ECMO implantation was performed early and promptly in a catheterization room in all of our patients who were diagnosed with profound CS (ie, early diagnosis and early treatment). Conversely, the extremely poor prognostic outcome for cardiac catheterization complications could be mainly due to both the complication being too serious (severe profound shock that required ECMO support) and the time that was consumed being too much (ie, CPCR and the PCI procedure required for temporally stabilizing the patient's hemodynamic condition) prior to the call for the ECMO team to help. Second, the good prognostic outcome in patients with fulminant acute myocarditis complicated by profound CS could be explained as this disease entity usually spontaneously recovers by itself only if the hemodynamic status is maintained to be stable. Thus, ECMO support in this clinical setting was considered as a bridge to provide the time for the heart and lung to take a rest and maintain the stable hemodynamics. Third, the favorable outcome of pediatric congenital diaphragmatic hernia was perhaps due to the following: (1) the hemodynamic instability usually developed slowly, which could be more easily discovered earlier and diagnosed in these patients; (2) infants usually have an inherent ability for regeneration and recover from divergent diseases; (3) the surgeon in our hospital had good experience to use appropriate strategic management for different congenital heart diseases.
Study Limitations
This study has limitations. First, this study was not a randomized-control clinical trial. Thus, as compared with the conventional setting of CPCR, the true additional benefit of ECMO support cannot be evaluated in these patients. Second, because ECMO support was merely considered as a bridging procedure for our patients who were in a critical condition, a protocol for long-term follow up was not designed in the current study. Accordingly, the present study did not provide information on the long-term outcome of the patients who had in-hospital survival. Finally, although the whole sample size was more than 130 patients in the current study, the sample size was still low in individual subgroups. Thus, it was rather difficult to make a relatively pertinent conclusion with respect to the findings from any individual subgroup.
Conclusion
In summary, the results of our observational study showed that for patients with profound CS refractory to conventional CPCR, ECMO support might provide a reasonable chance of survival. Both successful weaning from ECMO and an APACHE II score might serve as assessment parameters for risk stratification in such clinical settings for predicting prognostic outcome. However, further prospective, multi-centered and randomized control investigations are required for evaluating the additional benefit of ECMO support in the clinical setting of profound CS.
